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AT A GLANCE COMMENTARY:

Scientific knowledge on the subject
Bronchiectasis is a predominantly neutrophilic airways disease and despite this, there is persistent airways infection leading to chronic inflammation. The are no studies that have assessed neutrophil phenotype and how this alters neutrophil function in bronchiectasis. 

What the study adds to the field
This is the first study that demonstrates that there is a distinct subset of neutrophils that are reprogrammed in bronchiectasis. Bronchiectasis neutrophils have prolonged survival and delayed apoptosis. In stable bronchiectasis patients, blood neutrophils are pre-activated and reprogrammed leading to an inability to kill PAO1 as effectively as healthy controls or patients that have recovered from community acquired pneumonia, leading to persistent infection and inflammation. Blood neutrophil phagocytosis and killing of PAO1 are further impaired at start of exacerbations needing intravenous antibiotic therapy that improved following treatment. 
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ABSTRACT

Introduction
Excessive neutrophilic airways inflammation is the central feature of bronchiectasis, but little is known about neutrophils in bronchiectasis. The aim of this study was to assess blood neutrophil phenotype in bronchiectasis patients both whilst stable and during exacerbations.

Methods
In the clinically-stable arm of this study were 8 healthy volunteers, 8 mild and 8 severe bronchiectasis. In addition, 6 severe bronchiectasis patients were compared with 6 community-acquired pneumonia patients at the start and end of an exacerbation. We assessed neutrophils for spontaneous apoptosis rate, cell surface marker expression, degranulation, reactive oxygen species generation, phagocytosis and killing of Pseudomonas aeruginosa (PAO1). In addition, blood neutrophil function was compared to airway neutrophil function in bronchiectasis.

Results 
In stable bronchiectasis, compared to healthy volunteers, blood neutrophils had: significantly prolonged viability; delayed apoptosis; increased CD62L shedding; upregulated CD11b expression; increased myeloperoxidase release; impaired neutrophil phagocytosis and killing of PAO1.

Bronchiectatic airway neutrophils had significantly lower bacterial phagocytosis and killing, than their matched autologous blood neutrophils. Both blood and airway neutrophil phagocytosis and killing was impaired at the start of an exacerbation and improved following antibiotic treatment. 

In pneumonia patients, there was a significant improvement in phagocytosis and killing after treatment with antibiotics. On comparing phagocytosis and killing during exacerbations in bronchiectasis to pneumonia patients, there was no difference in phagocytosis, but there was significantly increased bacterial killing at the start and end of infection in pneumonia patients compared to bronchiectasis patients. 

Conclusion
In the stable state, in bronchiectasis, peripheral blood neutrophils are reprogrammed and have prolonged survival.This impairs their functional ability of bacterial phagocytosis and killing, thereby perpetuating the vicious circle in bronchiectasis. 


TEXT

Introduction 

Excessive neutrophilic airways inflammation is the central feature of bronchiectasis. This paradoxically both promotes bacterial colonization and perpetuates damage to the airways creating a vicious circle of bacterial colonization and inflammation [1]. The acute inflammatory response is a protective mechanism that is evolved to eliminate invading organisms and should ideally be self-limiting and lead to complete resolution [2-4]. However, there is failure of resolution of inflammation in bronchiectasis, leading to irreversible damage and dilatation of the bronchial airways with loss of mucociliary function. The driver for persistent neutrophilic airways inflammation in bronchiectasis is unknown. 

The traditional definition of the neutrophil, is that it is an effector of acute inflammation, and is short lived, with lifespan being measured in hours, and having a predefined set of functions [5]. However, this concept has been developing primarily by studying blood neutrophils (before extravasation to the tissues). It is subject to challenge as evidence emerges that neutrophil lifespan is considerably prolonged in response to stimuli such as granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor- (TNF-), interleukins (ILs), interferons and bacterial products [6-10] with consequent functional significance. During inflammation, leukocytes leave the circulation, enter new environments, and are exposed to multiple factors, such as cytokines, endogenous growth factors and bacterial products. Indeed, the activity of infiltrating neutrophils has been closely linked to disease evolution in a variety of clinical conditions [11-12]. Thereby these cells contribute not only to acute inflammatory reactions, but also to the evolution of a variety of chronic inflammatory diseases. 

Despite being a predominantly neutrophilic disease, bronchiectasis results in patients having recurrent chest infections. In more severe bronchiectasis there are high levels of sputum myeloperoxidase, free elastase activity and chemo attractants such as interleukin 8, leukotriene B4 and C5a [7,8], contributing to the persistent neutrophilic airways inflammation. Watt and colleagues have shown there is prolonged airway neutrophil survival in bronchiectasis [10] with less airway neutrophil apoptosis. Is this consequent to the altered inflammatory milieu in bronchiectasis? How does this impact on neutrophil function? There have been no studies to date assessing and phenotyping blood neutrophil function in bronchiectasis.

The aim of this study was to assess the phenotype of blood neutrophils in bronchiectasis patients whilst stable and during exacerbations.



Methods

Three study groups were included. Study 1: all patients were in a stable state (no infective exacerbation of bronchiectasis for at least 4 weeks prior to giving blood for this study) and included 8 patients with mild bronchiectasis, 8 with severe bronchiectasis and 8 healthy volunteers. Bronchiectasis patients that took part in the study were not on any inhaled corticosteroids, long term antibiotics or immunosuppressive therapy. All participants had 60 mls of blood taken and underwent a bronchoscopy with a broncho-alveolar lavage targeted to the most affected segment with bronchiectasis.

Study 2: Six severe bronchiectasis patients were recruited during an exacerbation requiring intravenous antibiotics and patients were reviewed at day 1 (start of antibiotic therapy) and day 14 (end of antibiotic therapy). All patients had 60 mls of blood taken and sputum induced on day 1 and day 14. 

Patients in study 2 were not the same patients as in study 1.

Study 3: Six community acquired pneumonia patients were recruited and reviewed at day 1 (hospital admission) and day 5 (when stable following antibiotic therapy). All patients had blood taken at day 1 and day 5. Patients required oral or intravenous antibiotics. We were not able to induce sputum in these patients. 

Bronchiectasis severity
The severity of bronchiectasis was based on the Bronchiectasis Severity Index (BSI) [13]. The BSI is a risk stratification tool for morbidity and mortality in bronchiectasis. The minimum score is 0 and the maximum score is 26. A score between 0-4 indicates mild disease; 5-8 indicates moderate disease and a score of >9 indicate severe disease. The BSI was calculated in all bronchiectasis patients taking part in the study. 

Consent
Lothian Research Ethics Committee gave consent for the study, 10/S1402/33. 

Isolation of blood and airways neutrophils
Freshly drawn blood was collected into 3.8% sodium citrate and granulocytes were subsequently isolated by dextran sedimentation and discontinuous Percoll gradient, as described [14]. 

Sputum and bronchoalveolar lavage was washed, treated with sputolysin and airways neutrophils isolated (described in detail in online supplement). Anti CD16 antibodies (Abcam) were used to identify neutrophils by flow cytometry. 

Blood neutrophil apoptosis at 20 hours
Freshly isolated blood neutrophils (at least 97% purity) was suspended at 10x106 cells/ml in Iscove's Modified Dulbecco's Media (IMDM) supplemented with 10% autologous serum and penicillin/streptomycin (1x). The assay was done on a 96 well flat-bottom plate. Following 20-hour incubation, apoptosis was examined by flow cytometry (Annexin-V (Roche) and propidium iodide (Sigma); BD FACS Calibur™) and confirmed by cytocentrifuge and Diff-Quick staining (Gamidor) [15]. 


Neutrophil activation
Freshly isolated neutrophils were activated with N-Formyl-methionyl-leucyl-phenylalanine, (fMLF) or vehicle control. Anti CD62L (BD Pharmigen ™) and CD11b (Alexa Fluor®) antibodies were added and the samples analyzed by flow cytometry (BD FACS Calibur™) [15]. 

Neutrophil degranulation and MPO measurement
Neutrophils were activated with cytochalsin B (Sigma Aldrich) and fMLF (Sigma Aldrich). Supernatants were collected and stored at -80°C. We measured myeloperoxidase activity (Sigma Aldrich) [16] with a chromogenic substrate assay. 

Reactive oxygen species generation
Freshly isolated blood neutrophils were loaded with dihydrorhodhamine (Sigma Aldrich). fMLF was added and superoxide release was measured by flow cytometry (BD FACS Calibur™) [15].

Neutrophil phagocytosis of Green fluorescent protein (GFP) labeled Pseudomonas and killing
GFP bacteria in the log phage were resuspended in PBS at a final concentration of 108 bacteria/ml. Following this, bacteria were opsonised with autologous serum for 1 hour at 37°C. The neutrophils (10x106 per condition) were then co-cultured with opsonised GFP PAO1 (1x108 bacteria per condition) and phagocytosis was measured by flow cytometry (BD FACS Calibur™) [17]. Cells were lysed with saponin (Sigma Aldrich, UK) before serial dilutions were plated out on Pseudomonas isolation agar. Colony counts were performed after 24 hours incubation of plates at 37°C in 5% CO2. (Full method in online supplement).

Bronchoscopy
All patients in study 1 underwent a bronchoscopy. Patients were sedated with midazolam +/- fentanyl. Bronchoalveolar lavage was done and samples obtained for neutrophil studies.

Inducing sputum
Sputum was induced as per standard protocol using 3% saline [18].

Statistical analysis
Flow cytometry analysis was performed using FlowJo v10.0.4 (Tree Star, Ashland, OR, USA). Results are presented as mean ± standard error of mean (SEM). Paired and unpaired t tests were used to compare two groups, where applicable. Data was analyzed by one-way ANOVA with a Bonferroni’s multiple comparison post hoc test (GraphPad Prism v6; GraphPad Software, La Jolla, CA, USA), when three groups were involved; significance was accepted with P values: *P < 0.05.







Results

Study design
The groups examined, and the timepoints for collection of biological samples, in the three elements of this study are shown in Figure 1.

Figure 1. The three groups recruited for this study. 
Study 1: All study participants – healthy volunteers, mild and severe bronchiectasis (no exacerbations for at least 4 weeks prior to taking part in the study) had blood obtained and underwent bronchoscopy. 
Study 2: Six severe bronchiectasis patients had blood and sputum obtained at the start (day 1) and end of antibiotic therapy (day 14).
 Study 3: Six pneumonia patients had blood obtained at the start (day 1) and end of antibiotic therapy (day 5).




Baseline demographics of the participants for Study 1 are shown in Table 1 (see online supplement Table E3 and E4, for baseline demographics of study 2&3 participants). In comparison to the patients with mild bronchiectasis, the severe group had significantly higher white cell counts, neutrophil counts and C reactive protein in blood; lower FEV1 % predicted, FVC % predicted and TLCO % predicted; higher rates of bacterial lung colonization; and a greater number of exacerbations and hospital admissions in the preceding year. 

Parameters	Healthy volunteersN=8	MildN=8	SevereN=8	P value
Age	52(6.8)	55(3.8)	64(2.2)	p=0.09
Gender (% female)	80%	40%	22%	p<0.0001
Cause of bronchiectasis-Idiopathic-Post infective	-	8 (100%)0	8 (100%)0	-
Total WCC(x109/L)	5.9(0.5)	6(0.5)	9.3(1.1)	p=0.005
Neutrophils(x109/L)	3.5(0.3)	3.3(0.3)	6.6(1.1)	p=0.001
Eosinophils(x109/L)	0.2(0.06)	0.2(0.04) 	0.2(0.06)	p=0.7
Monocytes(x109/L)	0.5(0.05)	0.5(0.03)	0.7(1)	p=0.7
ESR (mm/hr)	4.8(1)	6.7(1.8)	19.6(6.8)	p=0.1
CRP(mg/L)	3.2(1.1)	2.8(0.5)	16(7.4)	p=0.04
FEV1% predicted	-	95(5.5)	55(6.5)	p=0.0001
FVC % predicted	-	111(6)	84(6)	p=0.008
TLCO % predicted	-	94%(4.9)`	74%(7.8)	p=0.002
KCO % predicted	-	106%(4.5)	100%(7.2)	p=0.4
Chronic bacterial lung colonization- bacteria	-	3(37.5%)H.influenzae (3)	5(62.5%)P.aeruginosa (2)S.pneumoniae(2)H.influenzae 
(1) 	p<0.0001
Exacerbations in the last year 	-	0.4(0.3)	4.2(0.9)	p=0.002
Hospital admissions in the last year	-	0	0.7(0.2)	p=0.008
Table 1. Baseline demographics of study participants. Results expressed as mean (SEM). Chronic colonization defined as at least two isolates of an organism whilst clinically stable, at least 3 months apart over 1 year [13,19]. CRP= c reactive protein; ESR= erythrocyte sedimentation rate; FEV1= forced expiratory volume in 1 sec; FVC= forced vital capacity; KCO= transfer coefficient; TLCO= transfer factor for the lung for carbon monoxide; WCC= white cell count.


Blood neutrophil - spontaneous apoptosis 

Healthy blood neutrophils undergo well-described spontaneous apoptosis in culture; a process which can be altered by exposure to survival factors and by activation [19]. Blood neutrophils from both mild and severe bronchiectasis patients, in stable state, had greater viability, after 20 hours in culture, than healthy controls (p=0.002, p=0.005 respectively; figure 2). A correspondingly lower number of apoptotic neutrophils was observed (p=0.0003 for mild and p<0.0001 for severe), with no difference in the percentage of necrotic cells. The proportion of apoptotic neutrophils from severe bronchiectasis patients was reduced to ~50% of that of controls. There was no difference in the proportions of viable (p=0.4) or apoptotic cells (p=0.2) when comparing cells from mild and severe bronchiectasis patients. The effect was confirmed by light microscopic counting and assessment of total cell numbers demonstrated that these percentages were not skewed by an artefact of cell loss (data not shown).



Figure 2. Blood neutrophils from mild and severe bronchiectasis patients survived longer and underwent less apoptosis when compared to healthy volunteers. 
Blood neutrophils from mild and severe bronchiectasis patients in a stable state and healthy volunteers were cultured for 20 hours and cell viability (AnnV-ve/ PI-ve), apoptosis (AnnV +ve/PI-ve) and necrosis (AnnV+ve PI+ve) were assessed by flow cytometry. (A) N=8 in each group; percentage of viable, apoptotic and necrotic neutrophils in each group; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. One-way ANOVA with Bonferroni’s correction for multiple comparisons used for all 3 groups compared; comparing mild and severe bronchiectasis to healthy controls in viable, apoptotic and necrotic neutrophils (B)-(D) Representative flow cytometry plots and cytocentrifuge preparations at 20 hours (x1000 magnification). PI= propidium iodide. Black arrow: Dark pyknotic apoptotic nucleus. Grey arrow: multi lobulated viable nucleus.

In order to determine whether disease-related factors in the autologous serum used in these cultures differentially impacted the rate of neutrophil apoptosis, serum swap studies were conducted (Supplementary Figures E1 and E2). Firstly, spontaneous apoptosis was assessed in neutrophils from bronchiectasis patients in the presence of serum from healthy volunteers. After 20 hours, there was a significant reduction in the percentage of viable neutrophils when cultured in healthy control serum, as opposed to autologous serum (from 43.4% (±1.5) versus 50.7% (±3) respectively, p=0.02) and a significant increase in the percentage of apoptotic neutrophils (43% (±1.8) versus 38% (±2) respectively, p=0.02). There was no change in the percentage of necrotic neutrophils. In contrast, the nature of the serum used had no effect on the apoptosis of neutrophils from healthy volunteers  
These data raise that possibility that a factor in healthy serum, deficient in serum from bronchiectasis patients, can promote neutrophil apoptosis. However, the effect of serum was minimal compared to the overall disease-specific differences between the rates of spontaneous apoptosis of neutrophils, suggesting some level of reprogramming or activation of circulating blood neutrophils in bronchiectasis.

Blood neutrophil  - cell surface expression of CD62L and CD11b 
To evaluate the baseline activation status of unstimulated blood neutrophils from stable bronchiectasis patients, surface expression of CD62L and CD11b were contrasted to heathy controls (figure 3). Surface expression of CD62L on neutrophils from mild and severe bronchiectasis patients was significantly lower than on healthy control neutrophils (p=0.04 and p=0.02 respectively). There was no difference between mild and severe bronchiectasis. Compatible with this, CD11b levels were significantly higher on neutrophils from severe bronchiectasis patients compared to healthy controls (p=0.01) and mild bronchiectasis (p=0.01), but in this case neutrophils from patients with mild bronchiectasis were unchanged compared to controls.

Blood neutrophil - degranulation and reactive oxygen species generation 
To further evaluate the baseline activation status of blood neutrophils from stable bronchiectasis patients, myeloperoxidase (MPO) release from granules and superoxide generation were evaluated in unstimulated cells. A significantly higher level of MPO was detected in the supernatant of neutrophils from severe bronchiectasis patients, after 90 minutes in culture, compared to neutrophils from mild bronchiectasis patients (p=0.03) and healthy controls (p=0.04), with the latter two groups comparable. However, on comparison of superoxide release at baseline, there was no significant difference between neutrophils from healthy volunteers, mild and severe bronchiectasis patients; p=0.3 (figure 3). 




Figure 3. Blood neutrophils from stable bronchiectasis patients are more activated in the unstimulated state than neutrophils from healthy volunteers. 
(A)-(B) Blood neutrophils were isolated and cell surface markers CD62L and CD11b were measured by flow cytometry, when unstimulated. N=8 in each group. 
(C) Blood neutrophils were isolated and MPO measured by chromogenic assay, when unstimulated. N=8 in each group.  
 (D) Blood neutrophils were isolated, loaded with dihydrorhodamine and spontaneous reactive oxygen species generation was measured by flow cytometry. N=8 in each group.
One-way ANOVA with Bonferroni’s correction for multiple comparisons used for all 4 experiments; A, C&D: comparison of severe and mild bronchiectasis to healthy volunteers (used as control); B: comparison of healthy volunteers and mild bronchiectasis to severe bronchiectasis (used as control). Pooled data expressed as mean ± SEM.

Blood neutrophil - phagocytosis and killing of Pseudomonas aeruginosa
Having determined baseline differences in parameters that suggest differential activation of blood neutrophils from stable bronchiectasis patients, their functional efficacy in uptake and killing of pathogens was evaluated using a GFP P. aeruginosa strain PAO1 (Figure 4). Cells were spun at 300g for 5 minutes, supernatants discarded to remove free bacteria, and then cells lysed before plating. Phagocytosis was confirmed with z-stacking using confocal microscopy. In separate experiments phagocytosis was blocked by doing the experiments at 4°C, which demonstrated that at 4°C bacteria were still bound to cells but not internalized (data not shown). 
Data was analysed by gating the overall phagocytosis first (figure 4a). There was no difference in the overall phagocytosis between the groups. Next, we gated the neutrophils that had taken up much higher number of bacteria, as indicated by the mean fluorescence (MFLI). This was done at 50% of the total phagocytosis and we called this high MFLI phagocytosis.  There was significantly higher phagocytosis (comparing only the high MFLI and not total phagocytosis) by blood neutrophils from healthy volunteers compared to those from bronchiectasis patients, both the mild and severe groups (p=0.04; p=0.02 respectively). There was no difference between mild and severe groups, p=0.4. Comparison of the subsequent neutrophil-mediated bacterial killing showed significantly lower numbers of bacteria following exposure to healthy control neutrophils when compared to neutrophils from patients with mild or severe bronchiectasis (p=0.006; p=0.0003 respectively). There was no difference between mild and severe groups, p=0.1. These data demonstrate that despite increased activation, neutrophils from the blood of bronchiectasis patients have impaired phagocytosis and killing capacity (figure 4).

Figure 4. Impaired bacterial phagocytosis and killing by blood neutrophils from bronchiectasis patients compared to in healthy controls.
Blood neutrophils were isolated and co cultured with autologous serum-opsonized GFP-labelled P. aeruginosa PAO1 (at a concentration of 108/ml) for 15 minutes. Bacterial phagocytosis was measured by flow cytometry and serial dilutions of lysed cells were plated on Pseudomonas isolation agar, with colony forming units (cfu) counted 24 hours after plating to assess killing.
(A) Representative flow cytometry plot of phagocytosis, with high MFLI. Gates distinguish total cells having phagocytosed GFP-labelled bacteria, with “High MFL1 Phagocytosis”, indicating cells that had phagocytosed the most bacteria. (B) Pooled % neutrophil phagocytosis data, showing means +/- SEM of n=8 per group for Hi MFL1 gating. (C) Pooled bacterial killing in log scale units cfu/ml, data, showing median with IQR of n=8 per group. (B)-(C) One-way ANOVA with Bonferroni’s correction for multiple comparisons used for both experiments; with p values representing the comparison of severe and mild bronchiectasis to healthy volunteers (used as control). *P<0.05; **P<0.01, ***P<0.001.


Comparison of antibacterial function of blood and airways neutrophils from patients with bronchiectasis

Having established differential function of blood neutrophils isolated from bronchiectasis patients as compared to healthy controls, the antibacterial function of bronchoalveolar lavage-derived airway neutrophils from these patients was then evaluated (figure 5). Significantly lower levels of bacterial phagocytosis were observed for bronchoalveolar lavage-isolated neutrophils, when compared to donor-matched blood neutrophils, both from patients with mild and severe bronchiectasis (p<0.0001; p=0.0004 respectively). Comparison of the bacterial killing capacity showed a compatible significantly lower antibacterial function of bronchoalveolar lavage derived neutrophils compared to autologous blood neutrophils from the same patient, both in patients with mild and severe bronchiectasis (p=0.003; p=0.001 respectively). No differences between the antimicrobial functions of neutrophils from patients with mild and severe bronchiectasis was observed.  This demonstrates that bronchoalveolar lavage neutrophils have impaired function compared to blood neutrophils in bronchiectasis. 


Figure 5. Impaired antibacterial function of bronchoalveolar lavage (BAL) derived neutrophils compared to matched blood neutrophils from patients with mild and severe bronchiectasis. 
Neutrophils were isolated from BAL and blood from patients with mild and severe bronchiectasis, and co-cultured with serum-opsonized GFP PAO1 for 15 minutes (blood neutrophils) or 60 min (BAL neutrophils). Bacterial phagocytosis was measured by flow cytometry, and serial dilutions of lysed cells were plated on Pseudomonas isolation agar, with colony forming units (cfu) counted to assess killing. (A) Mild and (B) Severe bronchiectasis: Matched neutrophil phagocytosis data in blood and BAL derived neutrophils in the same patient; n=8 per group. (C) Mild and (D) Severe bronchiectasis: Matched bacterial killing in log scale units cfu/ml, in blood and BAL derived neutrophils in the same patient; n=8 per group. 2 way ANOVA showed no significant difference in the antibacterial activity between mild and severe bronchiectasis; p=0.2. **P<0.01; ***P<0.001; ****P<0.0001.




Comparison of antibacterial function of blood neutrophils from patients with bronchiectasis in stable and exacerbation states

The observation that blood neutrophils from patients with bronchiectasis had a higher baseline level of activation, with impaired antibacterial function, raised the question of the extent to which this might be further modulated by disease exacerbations. Matched samples collected from the same individuals at the beginning and end of an exacerbation were analysed, and compared to unmatched stable state controls. There was significantly higher bacterial phagocytosis by neutrophils collected at the end of an exacerbation compared those from the beginning of exacerbation (p=0.02). There was significantly more phagocytosis in the stable state compared to start of exacerbation, p=0.01. There was no difference in phagocytosis between the stable state and the end of exacerbation, p=0.9 (figure 6).
There was significantly higher killing at the end of exacerbation compared to beginning of exacerbation, p=0.03. There was significantly more killing in the stable state compared to start of exacerbation, p=0.02. There was no difference in bacterial killing between the stable state and the end of exacerbation, p=0.3. This demonstrates that blood neutrophil function is restored to levels comparable to the stable state in bronchiectasis, at the end of treatment of exacerbations. 

Figure 6. Phagocytosis and killing of bacteria by blood neutrophils significantly improves after antibiotic therapy in bronchiectasis.
(A)-(B) N=8 in stable state and N=6 at the start and end of exacerbation. Blood neutrophils isolated and phagocytosis and killing of GFP PAO1 assessed as previously described. Unpaired t-tests for comparison of stable state to start and end of exacerbation and paired t-tests for comparison of start to end of exacerbation. Pooled data presented as mean ± SEM for phagocytosis data and median (IQR) for bacterial killing data. 

Phagocytosis and killing by sputum derived neutrophils during exacerbations and comparison to stable state 

Having established that blood neutrophil function improved after treatment with antibiotics, the extent to which sputum-derived neutrophils had a similar response was assessed. There was significantly higher phagocytosis at the end of exacerbation compared to cells from the same donor taken at the beginning, p=0.008. There was more phagocytosis in the stable state compared to start of exacerbation although this observation, between unmatched donors, failed to reach statistical significance, p=0.08. There was no difference in phagocytosis between the stable state and the end of exacerbation, p=0.1.
There was significantly higher bacterial killing at the end of exacerbation compared to the beginning, p=0.02. There was more killing in the stable state compared to start of exacerbation p=0.02. There was no significant difference in killing between stable state and end of exacerbation, p=0.06, demonstrating that sputum neutrophil function is restored to stable state after treatment with antibiotics in exacerbations (figure 7).

Figure 7. Phagocytosis and killing of bacteria by airways neutrophils significantly improves after antibiotic therapy in bronchiectasis.
(A)-(B) N=8 in stable state and N=6 at the start and end of exacerbation. Airway neutrophils isolated and phagocytosis and killing of GFP PAO1 assessed as previously described. Unpaired t-tests for comparison of stable state to start and end of exacerbation and paired t-tests for comparison of start to end of exacerbation. Pooled data presented as mean ± SEM for phagocytosis data and median (IQR) for bacterial killing data.


COMMUNITY ACQUIRED PNEUMONIA

Comparison of bronchietasis versus pneumonia
In order to determine the disease specificity of the neutrophil phenotypes determined for individuals with bronchiectasis, 6 pneumonia patients (with no comorbidities) who were admitted to hospital, were also recruited and studied. Baseline demographics of this group are available in the online supplement (Table E3).


Phagocytosis and killing of GFP PAO1 by blood neutrophils 
The phagocytic and antibacterial properties of matched blood neutrophils collected at the beginning and day 5 of treatment of pneumonia, from the same patients, were compared. There was significant improvement in phagocytosis (p=0.03) and killing (p=0.03) at the end of treatment in pneumonia patients. 

Comparison of phagocytosis by blood neutrophils collected in CAP and bronchiectasis exacerbation showed no statistically significant difference at the beginning (p=0.7) or end of infection (p=0.1), between the two conditions. This suggested that the phagocytosis phenotype may not be disease specific, but a more general consequence of severe infection. In contrast, there was significantly lower bacterial killing in patients with bronchiectasis both at the start (p=0.0007) and end of exacerbation (p=0.003). These data demonstrate a bronchiectasis-specific neutrophil bacterial killing defect, that may be exacerbated by impaired phagocytosis. Furthermore, at the end of bronchiectasis exacerbations treated with antibiotics, this remains highly impaired in comparison to neutrophils from healthy volunteers with a recent pneumonia

Figure 8. There is significantly higher bacterial killing at the start and end of pneumonia compared to bronchiectasis. 
(A)-(B) N=6 in each group. Blood neutrophils isolated and phagocytosis and killing of GFP PAO1 assessed as previously described. Unpaired t-tests for all comparisons. Pooled data presented as mean ± SEM for phagocytosis data and median (IQR) for bacterial killing data. Bx= bronchiectasis; CAP = community- acquired pneumonia.



Discussion

We studied the functional phenotype of blood neutrophils in mild and severe bronchiectasis and compared it to the activity of blood neutrophils isolated from healthy volunteers. In bronchiectasis patients, we also assessed the function of airways neutrophils and compared it to blood neutrophil function from the same patient. In addition, we studied neutrophil function during bronchiectasis exacerbations and compared it to neutrophil function in healthy patients admitted with community-acquired pneumonia. The authors chose experiments with Pseudomonas aeruginosa, as this organism is associated with a worse outcome in bronchiectasis [13]. Future work investigating other pathogens in bronchiectasis is warranted. 

Blood neutrophils from bronchiectasis patients (both in mild and severe groups) had prolonged survival and delayed apoptosis when compared to healthy volunteers. Further studies demonstrated that when blood neutrophils from bronchiectasis patients were treated with serum from healthy volunteers, there was a reduction in viability and increased apoptosis in bronchiectasis neutrophils. However, the reverse was not true when treating healthy volunteers neutrophils with bronchiectasis serum. The overall effect of delayed apoptosis and prolonged survival of bronchiectasis neutrophils was more pronounced than the effect of serum swap. The reason for this remains to be determined, but the effect was minimal compared to the overall disease-specific differences between the rates of spontaneous apoptosis of neutrophils, suggesting some level of reprogramming or activation of circulating blood neutrophils in bronchiectasis. There was more CD62L shedding in mild and severe bronchiectasis compared to healthy volunteers. There was higher CD11b expression and myeloperoxidase release in severe bronchiectasis compared to healthy volunteers and mild bronchiectasis. There was no difference in reactive oxygen species generation in the three groups. There was significantly higher phagocytosis and bacterial killing of PAO1 in healthy volunteers compared to mild and severe bronchiectasis. Although the significantly higher proportion of females in the healthy volunteers group, compared to bronchiectasis patients, could be considered a minor limitation of this study, we have no reason to believe that this had any impact on the results of the study [20]. Studies have shown that older adults have impaired neutrophil migration that contributes to poorer outcomes during infection [21,22]. In this study, both in the stable state (healthy volunteers and bronchiectasis patients) and during exacerbations (pneumonia patients and severe bronchiectasis patients), there was no significant difference in the age of the study groups.

Having established that blood neutrophil phagocytosis and killing is impaired irrespective of disease severity, we wanted to explore whether airway neutrophil function was impaired. We demonstrated that phagocytosis and killing of PAO1 is impaired in airways neutrophils compared to blood neutrophils in both mild and severe bronchiectasis. Although the etiology of bronchiectasis is heterogeneous, to address this as a confounding factor, for the purpose of this study we included patients with idiopathic bronchiectasis only. Despite the neutrophils being preactivated, the phagocytic and bactericidal ability of blood and airways neutrophils is impaired (more marked in the airways) which suggests that the inflammatory milieu with myeloperoxidase and proteinase excess in patients with bronchiectasis is perhaps a contributory factor for this [8] leading to impaired function. It is known that inflammatory reprogramming of neutrophils leads to increased viability [23]. To the authors best knowledge airways neutrophil function in other disease such as COPD and cystic fibrosis conditions remain limited. Studies on broncho-alveolar lavage fluid neutrophils from other chronic lung diseases is warranted in the future. We hypothesize that airway neutrophils are also reprogrammed in bronchiectasis. 

In acute infective exacerbations of bronchiectasis, phagocytic and bactericidal activity of blood and airways neutrophil function improved with antibiotic therapy and was restored to levels comparable to the stable state. On comparison of bronchiectasis exacerbations and patients admitted with community-acquired pneumonia, there was no difference in blood neutrophil phagocytosis between the two groups; there was however significantly higher bacterial killing of PAO1 at the start and end of infection in community-acquired pneumonia patients compared to bronchiectasis exacerbations. Indeed, even at the end of treatment with antibiotics during bronchiectasis exacerbations, although phagocytosis and killing ability of neutrophils are restored to stable state, it was still lesser than in patients recovered from community acquired pneumonia suggesting that even at the end of exacerbation, there is failure of resolution of inflammation in bronchiectasis. This is important, as reduced functional activity of neutrophils would mean slower and lesser clearance of bacteria in bronchiectasis. Reduced phagocytosis and killing was not secondary to anti-pseudomonal antibodies as only 25% were positive for P aeruginosa in the severe group and in sub-group analysis excluding P aeruginosa, killing was still impaired (data not shown). We hypothesize that this failure of resolution could be secondary to persistence of reprogrammed neutrophils at the sites of inflammation or impaired clearance of these neutrophils. 


Bronchiectasis is a predominantly neutrophilic condition, where despite excess neutrophils, patients suffer daily cough, chronic sputum production and recurrent chest infections. The lung is continuously exposed to inhaled pathogen and it is the primary and secondary defense of the lung that maintains the microbiome of the lung. The excessive neutrophilic airways inflammation leads to damage of the bronchial wall and paradoxically promotes more airways inflammation and bacterial infection creating a vicious cycle [24, 1]. During natural resolution, polymorphonuclear neutrophils are required for antimicrobial defense [3], but these cells must then apoptose and are removed from the inflammatory site by macrophages [25]. Is this natural resolution impaired in bronchiectasis? There are no studies exploring the resolution mechanism in bronchiectasis or perhaps the lack of it, in the literature to date.

Apoptotic neutrophil death in situ has multiple pro-resolution actions [26-28]. Bronchiectasis neutrophils live longer and undergo delayed apoptosis compared to healthy volunteers. Given the number of neutrophils in bronchiectasis airways, late neutrophil apoptosis could have devastating consequences. Slowing neutrophil apoptosis would mean delayed removal by macrophages and delaying the process of resolution, thereby perpetuating the ongoing inflammation. Vandivier and colleagues had previously demonstrated that neutrophil elastase cleaves phosphatidylyserine receptor on neutrophils in cystic fibrosis and bronchiectasis, thereby impairing its clearance by macrophages [29]. This along with the data from our study suggest that bronchiectasis neutrophils undergo an alternative method of cell death. Could this be  NETosis or secondary necrosis? It is known that inefficient clearance of apoptotic cells results in secondary necrosis of cells and exacerbation of the inflammatory response [30]. Recent studies have demonstrated that in cystic fibrosis, there is increased NETosis as these neutrophils engage less in apoptosis [31]. This needs to be studied further in bronchiectasis.   

 
Our studies demonstrate that bronchiectasis neutrophils are reprogrammed. There is emerging evidence of subpopulations of mature and immature neutrophils coexisting in the circulation performing immunosuppressive or proinflammatory functions [32]. These have been identified as low-density neutrophils (LDNs) and are known to have phenotypic and functional heterogeneity [32]. LDNs have not been investigated in this study. Is there a release of chronic immature neutrophils in bronchiectasis or is there an imbalance between mature and immature neutrophils released? Antibiotics improve neutrophil function during exacerbations. However, neutrophils are preactivated even in the stable state. Do anti inflammatory or pro resolution mediators have a role as a long-term treatment in bronchiectasis? This needs to be investigated further. 

Overall, there was higher c-reactive protein, CD11b and myeloperoxidase generation in severe disease compared to mild disease. For the rest of the other parameters measured- there was no difference in viability, apoptosis, CD62L, reactive oxygen species generation, phagocytosis and killing between mild and severe groups. These suggest that the effect of the disease on peripheral blood neutrophil activity and function is more pronounced than disease severity. However, we accept that a limitation of the study is the size of the study and therefore further differences may have been found with a larger sample size. We accept that exacerbation data from the same patients in study 1 would be ideal but this is a technical difficulty. It was difficult to predict exacerbations in the stable patients and hence we recruited consecutive patients who had an exacerbation and presented to hospital. The data remains a valuable addition despite this. Another limitation is we assessed patients following 14 days of antibiotic therapy in bronchiectasis patients. A different time point was chosen for patients with pneumonia at day 5. All patients with pneumonia, were however clinically improved at day 5.  These time points were chosen to reflect end of antibiotic therapy. 

To the authors’ best knowledge, this is the first study demonstrating that peripheral blood neutrophils are reprogrammed in bronchiectasis. This is important preliminary work and would lead to further research in the area. Key future work would be to assess the airway neutrophil function. In this study, we have shown that in the vicious circle of infection and inflammation, the dynamics of cell death and clearance are not altered leading to overwhelming neutrophilic inflammation and thereby cytokine release. Neutrophil apoptosis and clearance and how this can be modified needs to be investigated further. 


Conclusion
In the stable state, peripheral blood neutrophils are reprogrammed and persist longer in bronchiectasis. This impairs their functional ability of bacterial phagocytosis and killing, thereby perpetuating the vicious circle in bronchiectasis. 
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